Despite bold ambitions in the Life Sciences Vision and NHS 10-Year Plan, uptake of new medicines remains slow. Can industry, government and providers finally bridge the gap between approval and access?
The UK stands at a crossroads in medicines policy. The government continues to champion life sciences as a central pillar of its industrial strategy, with the Life Sciences Vision and NHS 10-Year Plan both emphasising the UK’s potential as a global leader in innovation, research and patient-centred care.
Yet for industry, the reality is more complex. The breakdown of negotiations around the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) reflects this tension: companies are urged to invest in UK R&D and trials while facing financial constraints that threaten commercial viability and patient access.
Check out the rest of the article here
